The FTC has paused its antitrust case against major PBMs, citing a lack of commissioners. The lawsuit alleges unfair practices that inflated insulin prices.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Elevance Health (NYSE:ELV) and the rest of the health insurance providers stocks fared in Q4.
Although the S&P 500 is down 1.7% over the past six months, UnitedHealth’s stock price has fallen further to $523.02, losing shareholders 10.3% of their capital. This was partly driven by its softer quarterly results and may have investors wondering how to approach the situation.
Knowing which stocks to hold for the long term and which to sell before they drag down your portfolio is a challenge every investor faces at least once in their journey.
In a market obsessed with the next big growth story, it’s easy to overlook the quiet power of consistency. As tariff turbulence continues, some investors are diverting a portion of their portfolio funds to dividend stocks, which both provide immediate income and traditionally show less volatility compared to stocks that do not pay dividends.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the health insurance providers industry, including Cencora (NYSE:COR) and its peers.
Optum Rx is cutting prior authorizations on 80 drugs and updating payment models to improve reimbursements, benefiting independent pharmacies nationwide.
March 16, 2025 – 1:54 PM PDT
The Dow Jones Industrial Average has experienced significant turbulence in recent weeks, driven by economic uncertainty, shifting trade policies, and mixed corporate performances. As of mid-March 2025, the index has hovered near correction territory, down 9.3% from its December peak, reflecting broader
